Psychiatry Medical News about atypical antipsychotics schizophrenia glucoregulatory

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. 2008 Exclusive Survey—Earnings: Good news for primary care income

3. Medicare pay-for-reporting effort draws fire from frustrated doctors

4. Debunking Myths in the US Healthcare System

5. Omega-3 fatty acids for bipolar disorder

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Ethnic heterogeneity in glucoregulatory function during treatment with atypical antipsychotics in patients with schizophrenia
Journal of Psychiatric Research, 06/24/09

Ader M et al. - This is the first prospective study in psychiatric patients that quantified antipsychotic effects on the multiple metabolic processes that increase diabetes risk. Results indicate that ethnic minorities may have greater susceptibility to antipsychotic-induced glucoregulatory complications.

Methods

6-month, randomized, double-blind study to evaluate the effects of risperidone and olanzapine in patients with schizophrenia.
At baseline and weeks 6 and 24 quantified,

(1) total adiposity by DEXA
(2) visceral adiposity by abdominal CT
(3) insulin sensitivity (SI)
(4) pancreatic function (“disposition index”, DI) by intravenous glucose tolerance test.

Results

At baseline, groups (risperidone: n = 28; olanzapine: n = 31) were overweight or obese by body mass index (risperidone: 28.4 ± 5.4, olanzapine: 30.6 ± 7.0 kg/m2).
Both drugs induced weight gain (p < 0.004).
Total adiposity was increased by olanzapine at 6 weeks (p = 0.0006) and by both treatments at 24 weeks (p < 0.003).
Visceral adiposity was increased by olanzapine and risperidone by 24 weeks (p < 0.003).
SI did not deteriorate appreciably, although a downward trend was observed with risperidone.
Given known ethnic differences in adiposity and SI, secondary analysis in African American and Hispanic subjects was performed.
In this subset, olanzapine expanded both total and visceral adiposity (p < 0.02); no increase was observed with risperidone.
There were modest downward trends for SI with both treatments.
By week 24, olanzapine-treated subjects exhibited diminished DI (p = 0.033), indicating inadequate pancreatic compensation for insulin resistance.

<< Previous
Provider Monitoring and Pay-for-Performance When Multiple...

Next >>
Changes in Vitamin E Prescribing for Alzheimer Patients

Effectiveness of Switching to Aripiprazole From Atypical Antipsychotics in Patients With Schizophrenia
Clinical Neuropharmacology, 10/12/09 Relevance Score: 81%

A nation under siege: The 15-year outcome of Iraqi patients with schizophrenia in Babylon, Iraq
Journal of Mental Health, 10/19/09 Relevance Score: 79%

Aripiprazole versus other atypical antipsychotics for schizophrenia
Cochrane Reviews, 10/21/09 Relevance Score: 78%

Maternal schizophrenia and pregnancy outcome: Does the use of antipsychotics make a difference
Schizophrenia Research, 11/12/09 Relevance Score: 68%

Antipsychotic effects on auditory sensory gating in schizophrenia patients
European Neuropsychopharmacology, 10/21/09 Relevance Score: 68%